{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:26Z","timestamp":1790666546889,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sacituzumab govitecan (SG) was granted early access in France as third-line therapy for metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2\u2013mBC) metastatic breast cancer. This nationwide cohort study assessed its real-world use and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the French National Health Data System, we included all patients initiating SG between July 1, 2021, and December 31, 2023, with follow-up until June 30, 2024. Patient demographics, comorbidities, and prior treatments were recorded. Overall survival (OS) and time to treatment discontinuation (TTD) were estimated by Kaplan-Meier methods, and multivariable Cox models identified OS prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>3653 patients were included: 2527 mTNBC and 1,126 HR+\/HER2\u2013 mBC, with median ages of 58 and 61.5 years. Median OS was 11.0 months (95%CI: 10.4\u201311.7) for mTNBC and 11.4 months (95% CI: 10.7\u201312.4) for HR+\/HER2\u2013mBC. One-year survival was 47% and 48% and median TTD of 4.3 and 3.5 months, respectively. Poorer OS was independently associated with inpatient SG initiation and liver\/digestive metastases. In mTNBC, additional factors included brain metastases, respiratory disease, tobacco-related hospitalisation, multiple metastatic sites, and prior treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlights SG\u2019s clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03346-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:16:59Z","timestamp":1770311819000},"page":"1198-1208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive\/HER2-negative metastatic breast cancer"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-743X","authenticated-orcid":false,"given":"Aya Elhusseiny","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Desplas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Vignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Haddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"3346_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"3346_CR2","unstructured":"WHO. Breast cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer (accessed 15 June 2025)."},{"key":"3346_CR3","unstructured":"https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Panorama-des-cancers-en-France-edition-2024 Panorama des cancers en France - \u00e9dition 2024 - Ref: PANOKFR2024(accessed 28 Nov 2024)."},{"key":"3346_CR4","unstructured":"Triple-negative Breast Cancer | Details, Diagnosis, and Signs. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/types-of-breast-cancer\/triple-negative.html (accessed 21 May 2025)."},{"key":"3346_CR5","unstructured":"Cancer Statistics. SEER. https:\/\/seer.cancer.gov\/statistics\/index.html (accessed 21 May 2025)."},{"key":"3346_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","volume":"161","author":"WD den Brok","year":"2017","unstructured":"den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161:549\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"3346_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer. 2022;8:95.","journal-title":"npj Breast Cancer"},{"key":"3346_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/fon-2020-1021","volume":"17","author":"KE Skinner","year":"2021","unstructured":"Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Future Oncol. 2021;17:931\u201341.","journal-title":"Future Oncol"},{"key":"3346_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O'Reilly","year":"2021","unstructured":"O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol. 2021;12:164\u201382.","journal-title":"World J Clin Oncol"},{"key":"3346_CR10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/cancers16101791","volume":"16","author":"M Kesireddy","year":"2024","unstructured":"Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers. 2024;16:1791.","journal-title":"Cancers"},{"key":"3346_CR11","doi-asserted-by":"crossref","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15, 1212022).","DOI":"10.1186\/s13045-022-01341-0"},{"key":"3346_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"3346_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"3346_CR14","unstructured":"Understanding how Estrogen Receptor Positive (ER+) breast cancers evade the immune system - National Breast Cancer Foundation (NBCF) | Donate Online. https:\/\/nbcf.org.au\/project\/understanding-how-estrogen-receptor-positive-er-breast-cancers-evade-the-immune-system\/#:~:text=Estrogen%20Receptor%20Positive%20(ER%2B)%20breast%20cancer%20is%20the%20most,of%20all%20breast%20cancer%20cases.https:\/\/kusuri.ansm-intra.fr\/prodIntra\/ (accessed 3 Jun2025)."},{"key":"3346_CR15","unstructured":"Statut des r\u00e9cepteurs hormonaux du cancer du sein. https:\/\/www-breastcancer-org.translate.goog\/pathology-report\/hormone-receptor-status?_x_tr_sl=en&_x_tr_tl=fr&_x_tr_hl=fr&_x_tr_pto=rq&_x_tr_hist=true (accessed 6 June 2025)."},{"key":"3346_CR16","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"3346_CR17","unstructured":"Surveillance, Epidemiology, and End Results Program. SEER. https:\/\/seer.cancer.gov\/index.html (accessed 21 May 2025)."},{"key":"3346_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367:1783\u201391.","journal-title":"N Engl J Med"},{"key":"3346_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333.","journal-title":"Lancet"},{"key":"3346_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/onco.13878","volume":"26","author":"LM Spring","year":"2021","unstructured":"Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827\u201334.","journal-title":"Oncologist"},{"key":"3346_CR21","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.21.01374","volume":"39","author":"B Moy","year":"2021","unstructured":"Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor\u2013Negative: ASCO Guideline Update. JCO. 2021;39:3938\u201358.","journal-title":"JCO"},{"key":"3346_CR22","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989\u201329006.","journal-title":"Oncotarget"},{"key":"3346_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"3346_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","volume":"195","author":"J O\u2019Shaughnessy","year":"2022","unstructured":"O\u2019Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022;195:127\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"3346_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00439-5","volume":"8","author":"LA Carey","year":"2022","unstructured":"Carey LA, Loirat D, Punie K, Bardia A, Di\u00e9ras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer\u2014phase 3 ASCENT study subanalysis. npj Breast Cancer. 2022;8:72.","journal-title":"npj Breast Cancer"},{"key":"3346_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. npj Breast Cancer. 2024;10:33.","journal-title":"npj Breast Cancer"},{"key":"3346_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"3346_CR28","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. JCO. 2024;42:1738\u201344.","journal-title":"JCO"},{"key":"3346_CR29","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol. 2020;31:1709\u201318.","journal-title":"Ann Oncol"},{"key":"3346_CR30","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab Govitecan in Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer. JCO. 2022;40:3365\u201376.","journal-title":"JCO"},{"key":"3346_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/fon-2020-0163","volume":"16","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, et al. TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+\/HER2- Metastatic Breast Cancer. Future Oncol. 2020;16:705\u201315.","journal-title":"Future Oncol"},{"key":"3346_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572\u201380.","journal-title":"Breast Cancer"},{"key":"3346_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/OP.24.00242","volume":"21","author":"S Alaklabi","year":"2025","unstructured":"Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, et al. Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer. JCO Oncol Pr. 2025;21:620\u201328.","journal-title":"JCO Oncol Pr"},{"key":"3346_CR34","doi-asserted-by":"publisher","unstructured":"Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, et al. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol 14 (2024) https:\/\/doi.org\/10.3389\/fonc.2024.1362641.","DOI":"10.3389\/fonc.2024.1362641"},{"key":"#cr-split#-3346_CR35.1","unstructured":"Gorantla V, Choski R, Kudrik F, et al. Real-world sacituzumab govitecan treatment patterns and outcomes in second-line or later metastatic triple negative breast cancer: leveraging electronic health records and manual curation of a US database.Presented at: 42nd Annual Miami Breast Cancer Conference. March 6-9, 2025"},{"key":"#cr-split#-3346_CR35.2","unstructured":"Miami, Florida. Poster 31. U.S. (2025) https:\/\/www.targetedonc.com\/view\/sacituzumab-govitecan-shows-consistent-efficacy-in-real-world-mtnbc (accessed 2 May 2025)."},{"key":"3346_CR36","doi-asserted-by":"publisher","first-page":"175883592312004","DOI":"10.1177\/17588359231200454","volume":"15","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J, Shenoy S, Traut A, Harrach H, et al. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. 2023;15:175883592312004542023.","journal-title":"Ther Adv Med Oncol"},{"key":"3346_CR37","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, et al. Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer. 2024;130:1916\u201320.","journal-title":"Br J Cancer"},{"key":"3346_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","volume":"208","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, et al. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024;208:203\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"3346_CR39","doi-asserted-by":"crossref","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, et al. ESMO Guidance for Reporting Oncology Real-World Evidence (GROW). ESMO Real World Data and Digit Oncol 1 (1000032023).","DOI":"10.1016\/j.esmorw.2023.10.001"},{"key":"3346_CR40","doi-asserted-by":"publisher","unstructured":"Jourdain H, Meglio AD, Mansouri I, Desplas D, Zureik M, Haddy N. Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open 9 (2024) https:\/\/doi.org\/10.1016\/j.esmoop.2024.104083.","DOI":"10.1016\/j.esmoop.2024.104083"},{"key":"3346_CR41","doi-asserted-by":"crossref","unstructured":"Weill A, Nguyen P, Labidi M, Cadier B, Passeri T, Duranteau L, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ (372, n37).","DOI":"10.1136\/bmj.n37"},{"key":"3346_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.7326\/M22-0988","volume":"175","author":"J Botton","year":"2022","unstructured":"Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, et al. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France. Ann Intern Med. 2022;175:1250\u201357.","journal-title":"Ann Intern Med"},{"key":"3346_CR43","doi-asserted-by":"publisher","unstructured":"Jourdain H, Albin N, Monard A, Desplas D, Zureik M, Haddy N Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study. Clin Transl Gastroenterol (https:\/\/doi.org\/10.14309\/ctg.00000000000007732022).","DOI":"10.14309\/ctg.00000000000007732022)"},{"key":"3346_CR44","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev \u00c9pid\u00e9miol St\u00e9 Publique. 2017;65:S149\u201367.","journal-title":"Rev \u00c9pid\u00e9miol St\u00e9 Publique"},{"key":"3346_CR45","unstructured":"SNDS - regulations, processing, information to data subjects. EPI-PHARE. https:\/\/www.epi-phare.fr\/en\/regulation-snds\/ (accessed 28 Dec 2024)."},{"key":"3346_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey G, Jougla E, Fouillet A, H\u00e9mon D. Ecological association between a deprivation index and mortality in France over the period 1997 \u2013 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.","journal-title":"BMC Public Health"},{"key":"3346_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","volume":"60","author":"A Rachas","year":"2022","unstructured":"Rachas A, Gastaldi-M\u00e9nager C, Denis P, Barth\u00e9l\u00e9my P, Constantinou P, Drouin J, et al. The Economic Burden of Disease in France From the National Health Insurance Perspective: The Healthcare Expenditures and Conditions Mapping Used to Prepare the French Social Security Funding Act and the Public Health Act. Med Care. 2022;60:655\u201364.","journal-title":"Med Care"},{"key":"3346_CR48","unstructured":"l\u2019Assurance Maladie. M\u00e9thode de la cartographie des pathologies et des d\u00e9penses de l\u2019Assurance Maladie. https:\/\/www.assurance-maladie.ameli.fr\/etudes-et-donnees\/par-theme\/pathologies\/cartographie-assurance-maladie\/methode-cartographie-pathologies-depenses-assurance-maladie (accessed 30 Dec 2024)."},{"key":"3346_CR49","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.lanepe.2021.100158","volume":"8","author":"L Semenzato","year":"2021","unstructured":"Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health - Eur. 2021;8:100158.","journal-title":"Lancet Reg Health - Eur"},{"key":"3346_CR50","doi-asserted-by":"publisher","unstructured":"Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health \u2013 Europe 43(2024) https:\/\/doi.org\/10.1016\/j.lanepe.2024.100970.","DOI":"10.1016\/j.lanepe.2024.100970"},{"key":"3346_CR51","first-page":"1","volume":"08","author":"J Li","year":"2021","unstructured":"Li J. The exploration of the approach to data preparation for Chinese text analysis based on R Language. OALib. 2021;08:1\u20138.","journal-title":"OALib"},{"key":"3346_CR52","unstructured":"A Grammar of Data Manipulation. https:\/\/dplyr.tidyverse.org\/ (accessed 30 Dec 2024)."},{"key":"3346_CR53","unstructured":"ggplot2: Elegant Graphics for Data Analysis (3e). https:\/\/ggplot2-book.org\/ (accessed 30 Dec 2024)."},{"key":"3346_CR54","unstructured":"Therneau TM, until 2009) TL (original S->R port and R maintainer, Elizabeth A, Cynthia C. survival: package for Survival Analysis. (2024) https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html (accessed 30 Dec 2024)."},{"key":"3346_CR55","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong Y-N, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34:3308\u201314.","journal-title":"J Clin Oncol"},{"key":"3346_CR56","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1634\/theoncologist.2014-0184","volume":"19","author":"EO Jenkins","year":"2014","unstructured":"Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014;19:1076\u201383.","journal-title":"Oncologist"},{"key":"3346_CR57","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"R Wooster","year":"1994","unstructured":"Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to Chromosome 13q12-13. Science. 1994;265:2088\u201390.","journal-title":"Science"},{"key":"3346_CR58","doi-asserted-by":"publisher","first-page":"113422","DOI":"10.1016\/j.ejca.2023.113422","volume":"196","author":"A Galvin","year":"2024","unstructured":"Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer. 2024;196:113422.","journal-title":"Eur J Cancer"},{"key":"3346_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2022.05.027","volume":"172","author":"C Schaefers","year":"2022","unstructured":"Schaefers C, Seidel C, Bokemeyer F, Bokemeyer C. The prognostic impact of the smoking status of cancer patients receiving systemic treatment, radiation therapy, and surgery: A systematic review and meta-analysis. Eur J Cancer. 2022;172:130\u20137.","journal-title":"Eur J Cancer"},{"key":"3346_CR60","first-page":"100568","volume":"4","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Oskar S, Arunachalam A, Zu K, Kao Y-H, Chen C, et al. Real-world treatment patterns and outcomes of first-line immunotherapy among patients with advanced nonsquamous NSCLC Harboring BRAF, MET, or HER2 alterations. JTO Clin Res Rep. 2023;4:100568.","journal-title":"JTO Clin Res Rep"},{"key":"3346_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71788-z","volume":"10","author":"MA\u00c1 Machado","year":"2020","unstructured":"Machado MA\u00c1, de Moura CS, Chan K, Curtis JR, Hudson M, Abrahamowicz M, et al. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Sci Rep. 2020;10:14607.","journal-title":"Sci Rep"},{"key":"3346_CR62","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/OP.2025.21.10_suppl.568","volume":"21","author":"S Appukkuttan","year":"2025","unstructured":"Appukkuttan S, McManus HD, Liao N, Curry L, Andres R, Kalayeh B, et al. Real-world discontinuation rates among patients with metastatic castration-sensitive prostate cancer who initiated novel androgen receptor inhibitors: A US claims analysis. JCO Oncol Pr. 2025;21:568.","journal-title":"JCO Oncol Pr"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03346-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03346-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03346-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:02:10Z","timestamp":1774864930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03346-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,20]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03346-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with French legislation on the reuse of health data for research purposes. The use of data from the French National Health Data System (SNDS) was authorised by the French data protection authority (CNIL). All data were anonymized before analysis, and no identifiable patient information was accessed. As such, individual informed consent was not required. The SNDS includes all mandatory health insurance reimbursement data of the French population, in particular data from the processing of health care reimbursements (electronic or paper treatment sheet) and data from health establishments (PMSI). EPI-PHARE has permanent regulatory access to the data from the SNDS via its constitutive bodies ANSM and CNAM, in application of the provisions of the French Decree No. 2016-1871 of 26 December 2016 relating to the processing of personal data called the \u2018National Health Data System\u2019 15, the French law articles Art. R. 1461-1316 and R. 1461-1417 from the French Public Health Code and the CNIL decision CNIL-2016-316.18. In accordance, this work did not require any specific opinion from the French Ethical and Scientific Committee for Research, Studies and Evaluations health (CESREES) nor approval from the CNIL. All requests in the database were made by duly authorised people. The study was registered on the study register of EPIPHARE concerning studies from SNDS data under the reference T-2024-01-481.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As this study used anonymized data from a national database, consent for publication was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}